Skip to main content
REGN
NASDAQ Life Sciences

杜皮森（Dupixent）获得欧盟批准，用于治疗2至11岁儿童慢性荨麻疹，扩大关键市场

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$749.36
Mkt Cap
$79.158B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

Regeneron和Sanofi的畅销药杜皮森（Dupixent）获得欧盟批准，用于治疗2至11岁儿童的中度至重度慢性自发性荨麻疹（CSU）。这使得杜皮森（Dupixent）成为欧盟首个针对该特定患者人群的靶向药物，显著扩大了其关键收入来源产品的可及市场。该批准基于LIBERTY-CUPID临床研究计划的积极数据，证明了杜皮森（Dupixent）的疗效和安全性特征。这一监管胜利是重要的积极发展，强化了杜皮森（Dupixent）的市场领导地位，并有助于雷金诺（Regeneron）的长期收入增长，继该公司最近发布的一系列正面和负面消息之后。投资者现在将关注同一适应症的待决美国补充生物制剂许可申请的结果。

在该公告发布时，REGN的交易价格为$749.36，交易所为NASDAQ，所属行业为Life Sciences，市值约为$791.6亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article